Oligodendrocyte Precursor Cell Activation to Restore Structural Connectome Integrity

Oligodendrocyte Precursor Cell connectomics market 43% proposed
Composite
41%
Novelty
70%
Feasibility
65%
Impact
40%
Mechanistic
50%
Druggability
50%
Safety
35%
Confidence
35%

Mechanistic description

Oligodendrocyte Precursor Cell Activation to Restore Structural Connectome Integrity

Evidence for (5)

  • Myelin breakdown is an early, underrecognized feature of AD pathophysiology

    PMID:29186337

  • Hub regions connected by long-range white matter tracts that are particularly vulnerable

    PMID:20644199

  • Clemastine promotes OPC differentiation and remyelination in cuprizone and EAE models

    PMID:25502559

  • Siponimod (Mayzent) FDA-approved for secondary progressive MS

    PMID:25503441

  • Network-level changes include reduced white matter integrity measurable by diffusion MRI

    PMID:24879878

Evidence against (5)

  • Myelin changes in AD may be secondary to axonal degeneration - primary vs secondary unresolved

    PMID:29422609

  • White matter hyperintensities correlate with vascular pathology, not primary OPC dysfunction

    PMID:29186337

  • Clemastine not advanced to AD clinical trials - off-target antihistamine effects

    PMID:25502559

  • Siponimod failed in secondary progressive MS - S1P modulation insufficient for established myelin pathology

    PMID:25503441

  • Aged human OPCs have substantially reduced differentiation capacity vs young animals

    PMID:29186337